Literature DB >> 15811621

Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations.

Eva Wardelmann1, Nadja Thomas, Sabine Merkelbach-Bruse, Katharina Pauls, Nicola Speidel, Reinhard Büttner, Heiner Bihl, Claudia C Leutner, Thomas Heinicke, Peter Hohenberger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15811621     DOI： 10.1016/S1470-2045(05)70097-8

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  62 in total

1.  Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia.

Authors:  Akane Tsujimura; Hitoshi Kiyoi; Yukimasa Shiotsu; Yuichi Ishikawa; Yumiko Mori; Hiroshi Ishida; Tsutomu Toki; Etsuro Ito; Tomoki Naoe
Journal:  Int J Hematol       Date:  2010-10-05       Impact factor: 2.490

2.  A quality control program for mutation detection in KIT and PDGFRA in gastrointestinal stromal tumours.

Authors:  Isabelle Hostein; Maria Debiec-Rychter; Sylvianne Olschwang; Pierre-Paul Bringuier; Louisa Toffolati; David Gonzalez; Sébastien Forget; Fabienne Escande; Lucyna Morzuch; Elena Tamborini; Nicolas Faur; Silvana Pilotti; Paolo Dei Tos; Jean-François Emile; Jean-Michel Coindre
Journal:  J Gastroenterol       Date:  2011-02-01       Impact factor: 7.527

3.  [Surgical considerations for gastrointestinal stroma tumor].

Authors:  P Hohenberger; E Wardelmann
Journal:  Chirurg       Date:  2006-01       Impact factor: 0.955

4.  Double resistance to imatinib and AMG 706 caused by multiple acquired KIT exon 17 mutations in a gastrointestinal stromal tumour.

Authors:  Florian Grabellus; Peter Ebeling; Karl Worm; Sien-Yi Sheu; Gerald Antoch; Andrea Frilling; Kurt W Schmid
Journal:  Gut       Date:  2007-07       Impact factor: 23.059

5.  SOCS1 gene therapy has antitumor effects in imatinib-resistant gastrointestinal stromal tumor cells through FAK/PI3 K signaling.

Authors:  Takahito Sugase; Tsuyoshi Takahashi; Satoshi Serada; Minoru Fujimoto; Tomoharu Ohkawara; Kosuke Hiramatsu; Toshirou Nishida; Seiichi Hirota; Yurina Saito; Koji Tanaka; Yasuhiro Miyazaki; Tomoki Makino; Yukinori Kurokawa; Makoto Yamasaki; Kiyokazu Nakajima; Kazuhiro Hanasaki; Tadamitsu Kishimoto; Masaki Mori; Yuichiro Doki; Tetsuji Naka
Journal:  Gastric Cancer       Date:  2018-04-05       Impact factor: 7.370

6.  Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells.

Authors:  Sebastian Bauer; Joshua A Parry; Thomas Mühlenberg; Matthew F Brown; Danushka Seneviratne; Payel Chatterjee; Anna Chin; Brian P Rubin; Shih-Fan Kuan; Jonathan A Fletcher; Stefan Duensing; Anette Duensing
Journal:  Cancer Res       Date:  2009-12-22       Impact factor: 12.701

Review 7.  Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies.

Authors:  Joseph Vadakara; Margaret von Mehren
Journal:  Hematol Oncol Clin North Am       Date:  2013-10       Impact factor: 3.722

8.  Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.

Authors:  Michael C Heinrich; Robert G Maki; Christopher L Corless; Cristina R Antonescu; Amy Harlow; Diana Griffith; Ajia Town; Arin McKinley; Wen-Bin Ou; Jonathan A Fletcher; Christopher D M Fletcher; Xin Huang; Darrel P Cohen; Charles M Baum; George D Demetri
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

Review 9.  [Grayzone lymphoma. Clinical relevance].

Authors:  S Hartmann; M L Hansmann
Journal:  Pathologe       Date:  2010-02       Impact factor: 1.011

10.  Molecular imaging of solid tumors: exploiting the potential.

Authors:  Wim J G Oyen; Winette T A van der Graaf
Journal:  Nat Rev Clin Oncol       Date:  2009-10       Impact factor: 66.675
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.